Qlaira: first COC licensed for heavy menstrual bleeding
Review
OA: closed
CC0
AI-generated summary
Qlaira, a combined oral contraceptive containing estradiol valerate and dienogest, is the first such product licensed for treating heavy menstrual bleeding in women without organic pathology.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Abstract Qlaira (estradiol valerate plus dienogest) is the first combined oral contraceptive to gain a licence for the treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Dr Paula Briggs discusses its place in the treatment of heavy menstrual bleeding. Copyright © 2011 Wiley Interface Ltd
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-05-11T04:02:56.979793+00:00
- unpaywall
- last seen: 2026-10-22T06:24:31.118836+00:00
License: CC0
· commercial use OK